Crescent Biopharma posts smaller-than-expected Q2 net loss 

Overview

• US oncology developer's Q2 net loss beat analyst expectations

• Income from operations for Q2 beat analyst expectations

• Company completed $143.7 mln public offering, extending cash runway into second half of 2028

Outlook

• Company expects cash runway to extend into second half of 2028

Result Drivers

• RD SPENDING - Co said higher Q2 research and development expenses were driven by increased costs for chemistry, manufacturing, controls, clinical activity and higher personnel-related costs

• PIPELINE ADVANCEMENT - Co cited ongoing and planned clinical trials for CR-001, CR-002 and CR-003 as key operational focus during the quarter

• GA COSTS - Co said Q2 general and administrative expenses declined due to lower personnel and professional service costs, partially offset by higher office, facilities, software and public company expenses

Company press release: ID:nGNX6W928W

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Crescent Biopharma Inc is $30.00, about 103.1% above its July 29 closing price of $14.77

Reuters Recommended Reads

• July 29 - Viking Therapeutics reports Q2 milder-than-expected net loss as obesity trials advance

• July 29 - Dyne Therapeutics reports larger-than-expected Q2 net loss per share

• July 29 - Processa buys Vidya Therapeutics, raises $200 million for drug trials

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)